Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ancizu, Saioa, Moreno, Elsa, Torres, Enrique, Burguete, Asunción, Pérez-Silanes, Silvia, Benítez, Diego, Villar, Raquel, Solano, Beatriz, Marín, Adoración, Aldana, Ignacio, Cerecetto, Hugo, González, Mercedes, Monge, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254273/
https://www.ncbi.nlm.nih.gov/pubmed/19553897
http://dx.doi.org/10.3390/molecules14062256
_version_ 1783373685182169088
author Ancizu, Saioa
Moreno, Elsa
Torres, Enrique
Burguete, Asunción
Pérez-Silanes, Silvia
Benítez, Diego
Villar, Raquel
Solano, Beatriz
Marín, Adoración
Aldana, Ignacio
Cerecetto, Hugo
González, Mercedes
Monge, Antonio
author_facet Ancizu, Saioa
Moreno, Elsa
Torres, Enrique
Burguete, Asunción
Pérez-Silanes, Silvia
Benítez, Diego
Villar, Raquel
Solano, Beatriz
Marín, Adoración
Aldana, Ignacio
Cerecetto, Hugo
González, Mercedes
Monge, Antonio
author_sort Ancizu, Saioa
collection PubMed
description Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC(50) values in the same order as the anti-chagasic drug, nifurtimox.
format Online
Article
Text
id pubmed-6254273
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Molecular Diversity Preservation International
record_format MEDLINE/PubMed
spelling pubmed-62542732018-11-30 Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs Ancizu, Saioa Moreno, Elsa Torres, Enrique Burguete, Asunción Pérez-Silanes, Silvia Benítez, Diego Villar, Raquel Solano, Beatriz Marín, Adoración Aldana, Ignacio Cerecetto, Hugo González, Mercedes Monge, Antonio Molecules Article Neglected diseases represent a major health problem. It is estimated that one third of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, affects approximately 20 million people. Quinoxalines display great activities against TB and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides (CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC(50) values in the same order as the anti-chagasic drug, nifurtimox. Molecular Diversity Preservation International 2009-06-22 /pmc/articles/PMC6254273/ /pubmed/19553897 http://dx.doi.org/10.3390/molecules14062256 Text en © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Ancizu, Saioa
Moreno, Elsa
Torres, Enrique
Burguete, Asunción
Pérez-Silanes, Silvia
Benítez, Diego
Villar, Raquel
Solano, Beatriz
Marín, Adoración
Aldana, Ignacio
Cerecetto, Hugo
González, Mercedes
Monge, Antonio
Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title_full Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title_fullStr Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title_full_unstemmed Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title_short Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
title_sort heterocyclic-2-carboxylic acid (3-cyano-1,4-di-n-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254273/
https://www.ncbi.nlm.nih.gov/pubmed/19553897
http://dx.doi.org/10.3390/molecules14062256
work_keys_str_mv AT ancizusaioa heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT morenoelsa heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT torresenrique heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT burgueteasuncion heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT perezsilanessilvia heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT benitezdiego heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT villarraquel heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT solanobeatriz heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT marinadoracion heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT aldanaignacio heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT cerecettohugo heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT gonzalezmercedes heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs
AT mongeantonio heterocyclic2carboxylicacid3cyano14dinoxidequinoxalin2ylamidederivativesashitsforthedevelopmentofneglecteddiseasedrugs

Ejemplares similares